Structure Therapeutics has a promising pipeline of product candidates, including GSBR-1290, a GLP-1R agonist for diabetes and obesity, and APJR and LPA1R agonists and antagonists for various ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results